European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK
Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland
Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Germany Health | Immunotherapy | Merck | Merkel Cell Carcinoma | Pfizer | Pharmaceuticals | Skin | Skin Cancer | Switzerland Health